Patients taking substrates, inhibitors, or inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan
Concurrent therapy with strong inhibitors or inducers of cytochrome P family , subfamily A, polypeptide  (CYPA) or cytochrome P family , subfamily C, polypeptide  (CYPC) due to concerning possible drug-drug interactions
Caution should be exercised when dosing navitoclax concurrently with cytochrome P, family , subfamily C, peptide  (CYPC) and cytochrome P, family , subfamily C, peptide  (CYPC) substrates; common CYPC substrates include paclitaxel, statins, and glitazones, whereas CYPC substrates include phenytoin; when possible, investigators should switch to alternative medications or monitor the patients closely; cytochrome P, family , subfamily A (CYPA) inhibitors such as ketoconazole and clarithromycin are not allowed  days prior to the first dose of navitoclax or during navitoclax administration
Treatment with strong cytochrome P, family , subfamily C, polypeptide  (CYPC), cytochrome P, family , subfamily A, polypeptide  (CYPA), and cytochrome P, family , subfamily C, polypeptide  (CYPC) inhibitors and/or inducers must be discontinued at least  week before administration of the first dose of study drug
Subjects who are currently receiving therapy with a potent cytochrome P, family , subfamily A, polypeptide  (CYPA) inducer or inhibitor (e.g. clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir)
Patients receiving any medications that are known to be strong inducers or inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA), or sensitive substrates of CYPA, cytochrome P, family , subfamily A, polypeptide  (CYPA), cytochrome P, family , subfamily C, polypeptide  (CYPC), cytochrome P, family , subfamily C, polypeptide  (CYPC) or permeability glycoprotein (P-gp) with a narrow therapeutic index
Patients currently receiving (or unable to stop use at least  week prior to receiving the st dose of AZD) medications or herbal supplements known to be potent inhibitors of cytochrome P, family , subfamily C, polypeptide  (CYPC) and potent inhibitors or inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA) are ineligible; patients are eligible if they stop use of these compounds at least  week prior to receiving any treatment on this protocol
Patients receiving any medications or substances that are strong inhibitors or inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA), CYPA, cytochrome P, family , subfamily C, polypeptide  (CYPC), CYPC, cytochrome P, family , subfamily A, polypeptide  (CYPA), UDP glycosyltransferase  family, polypeptide A (UGTA), P-glycoprotein, or breakpoint cluster region pseudogene (BCRP) are ineligible; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Concomitant therapy with any drugs shown to have major interactions with nortriptyline (i.e. known inhibitors of cytochrome P family  subfamily D member  [CYPD]) and use during the -day period prior to study start
Drugs that affect the cytochrome P family , subfamily A, polypeptide  (CYPA) systems are allowed but should be used with caution depending on specific kinase inhibitor used
Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with ceritinib and for the duration of participation:\r\n* Medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes\r\n* Strong inhibitors or strong inducers of cytochrome P, family , subfamily A, polypeptide / (CYPA/)\r\n* Medications with a low therapeutic index that are primarily metabolized by CYPA/, and/or cytochrome P, family , subfamily C, polypeptide  (CYPC)\r\n* Therapeutic doses of warfarin sodium (Coumadin) or any other Coumadin-derived anti-coagulant; anticoagulants not derived from warfarin are allowed (e.g., dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms (non-central nervous system [CNS]), dose must have been stabilized (or decreasing) for at least  days before first dose of study treatment\r\n* Enzyme-inducing anticonvulsive agents\r\n* Herbal supplements
Treatment with strong inhibitors and/or inducers of cytochrome P (CYP) subfamily IIIA, polypeptide  (A), cytochrome P, family , subfamily C, polypeptide  (CYPC) or cytochrome P, family , subfamily C, polypeptide  (CYPC) within  week preceding the first dose of study drug
Concomitant use of medications that are known cytochrome p family  subfamily A member  (CYPA) substrates
Patients taking medications with narrow therapeutic indices that are metabolized by cytochrome P (CYP), including warfarin sodium (Coumadin) are ineligible; patients on strong cytochrome P, family , subfamily A (CYPA) inhibitors will also be excluded
Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with ceritinib and for the duration of participation:\r\n* Medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes\r\n* Strong inhibitors or strong inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA)/cytochrome P, family , subfamily A, polypeptide  ()\r\n* Medications with a low therapeutic index that are primarily metabolized by CYPA/, cytochrome P, family , subfamily C, polypeptide  (CYPC) and/or cytochrome P, family , subfamily C, polypeptide  (CYPC) \r\n* Therapeutic doses of warfarin sodium (Coumadin) or any other Coumadin-derived anti-coagulant\r\n* Anticoagulants not derived from warfarin are allowed (eg, dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms (non-central nervous system [CNS]), dose must have been stabilized (or decreasing) for at least  days before first dose of study treatment\r\n* Enzyme-inducing anticonvulsive agents\r\n* Herbal supplements
Are taking strong or moderate cytochrome P, family , subfamily A, polypeptide  (CYPA) or cytochrome P, family , subfamily C, polypeptide  (CYPC) inducers, or CYPA, cytochrome P, family , subfamily C, polypeptide  (CYPC) and cytochrome P, family , subfamily C, polypeptide  (CYPC) substrates with a narrow therapeutic index; patients may switch to an alternative any time prior to day  of trial drug administration
Patients receiving any medications or substances that are strong inducers/inhibitors or substrates of cytochrome P, family , subfamily A, polypeptide  (CYPA)/, cytochrome P, family , subfamily C, polypeptide  (CYPC), CYPC, or CYPC are ineligible; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with ceritinib and for the duration of the study participation: \r\n* Medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes \r\n* Strong inhibitors or strong inducers of cytochrome P, family , subfamily A, polypeptide /cytochrome P, family , subfamily A, polypeptide  (CYPA/)\r\n* Medications with a low therapeutic index that are primarily metabolized by CYPA/, cytochrome P, family , subfamily C, polypeptide  (CYPC) and/or cytochrome P, family , subfamily C, polypeptide  (CYPC) \r\n* Therapeutic doses of warfarin sodium (Coumadin) or any other Coumadin-derived anti-coagulant; anticoagulants not derived from warfarin are allowed (e.g., dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids\r\n* Enzyme-inducing anticonvulsive agents \r\n* Herbal supplements
Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with ceritinib and for the duration of participation\r\n* Medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes \r\n* Strong inhibitors or strong inducers of cytochrome P, family , subfamily A, polypeptide / (CYPA/) \r\n* Medications with a low therapeutic index that are primarily metabolized by CYPA/, cytochrome P, family , subfamily C, polypeptide  (CYPC) and/or cytochrome P, family , subfamily C, polypeptide  (CYPC) \r\n* Therapeutic doses of warfarin sodium (Coumadin) or any other Coumadin-derived anti-coagulant; anticoagulants not derived from warfarin are allowed (eg, dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms (non-central nervous system [CNS]), dose must have been stabilized (or decreasing) for at least  days before first dose of study treatment\r\n* Enzyme-inducing anti-convulsive agents\r\n* Herbal supplements
Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with ceritinib and for the duration of participation:\r\n* Medication with a known risk of prolonging the QT interval or inducing torsades de pointes \r\n* Strong inhibitors or strong inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA)/ \r\n* Medications with a low therapeutic index that are primarily metabolized by CYPA/, cytochrome P, family , subfamily C, polypeptide  (CYPC) and/or cytochrome P, family , subfamily C, polypeptide  (CYPC) \r\n* Therapeutic doses (defined as doses need to achieve target INR > .) of warfarin sodium (Coumadin) or any other Coumadin-derived anti-coagulant; anticoagulants not derived from warfarin are allowed (e.g., dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids\r\n* Enzyme-inducing anticonvulsive agents\r\n* Herbal supplements
Use of cytochrome P, family , subfamily A, polypeptide  (CYPA) inducers including hepatic enzyme-inducing anticonvulsants (phenytoin, fosphenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) within  weeks prior to start of study treatment
Patients who are currently receiving treatment with agents that are metabolized solely through cytochrome P family , subfamily A, polypeptide / (CYPA/) and have a narrow therapeutic index or are strong cytochrome P family , subfamily C, polypeptide  (CYPC) inhibitors; or are receiving treatment with agents that carry a risk for QT prolongation and are CYPA substrates
Patients who are receiving treatment with medications known to be moderate and strong inhibitors or inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA)/cytochrome P, family , subfamily A, polypeptide  () or drugs metabolized by cytochrome P, family , subfamily B, polypeptide  (CYPB) or cytochrome P, family , subfamily C, polypeptide  (CYPC) that have narrow therapeutic index, and that cannot be discontinued before starting treatment with LDE
Caution should be exercised when dosing navitoclax concurrently with cytochrome P, family , subfamily C, polypeptide  (CYPC) and cytochrome P, family , subfamily C, polypeptide  (CYPC) substrates; common CYPC substrates include paclitaxel, statins, and glitazones, whereas CYPC substrates include phenytoin and warfarin; when possible, investigators should switch to alternative medications or monitor the patients closely (particularly in the case of medications that have a narrow therapeutic window such as warfarin; use of warfarin is specifically prohibited while on study); cytochrome P, family , subfamily A (CYPA) inhibitors such as ketoconazole and clarithromycin are not allowed  days prior to the first dose of navitoclax or during navitoclax administration; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product; patient instructions and information of possible drug interactions will be given to all patients upon enrollment in this study
The following medications are prohibited during the study: \r\n* Substrates of cytochrome P, family , subfamily B, polypeptide  (CYPB), cytochrome P, family , subfamily C, polypeptide  (CYPC), cytochrome P, family , subfamily C, polypeptide  (CYPC), and cytochrome P, family , subfamily C, polypeptide  (CYPC) with a narrow therapeutic index, including paclitaxel, phenytoin, warfarin, omeprazole \r\n* Substrates of cytochrome P, family , subfamily A, polypeptide  (CYPA) with a narrow therapeutic index, including alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus\r\n* Strong CYPC inhibitors, including gemfibrozil\r\n* Strong CYPA/ inhibitors, including clarithromycin, itraconazole, ketoconazole
Strong cytochrome P, family , subfamily A, polypeptide  (CYP A) inhibitors (e.g., clarithromycin, human immunodeficiency virus [HIV] protease inhibitors, and itraconazole), given potential interactions with atorvastatin (atorvastatin calcium)
Concomitant use of drugs that are cytochrome P, family , subfamily A, polypeptide  (CYPA), cytochrome P, family , subfamily A, polypeptide  (CYPA), or cytochrome P, family , subfamily D, polypeptide  (CYPD) substrates
Drugs that affect the cytochrome P family  subfamily A polypeptide  (CYPA) system (inducers/inhibitors/substrates) are allowed but should be used with caution depending on specific kinase inhibitor used; dietary supplements will be discouraged; however, their use may be allowed on a case by case basis per the discretion of the investigator after consultation with an oncology pharmacist
Patients on drugs that are strong cytochrome P, family , subfamily A, polypeptide  (P CYPA) modifiers; these drugs should be stopped  half-lives prior to starting investigational agents with temsirolimus; the strong inducing or inhibiting agents should not restart until  week after the end of the study treatment; NOTE: we will allow replacement of steroids (with either prednisone or hydrocortisone) in patients with adrenalectomy
Treatment with drugs that are substrates of cytochrome P, family , subfamily A, polypeptide  (CYPA), cytochrome P, family , subfamily D, polypeptide  (CYPD), and cytochrome P, family , subfamily A, polypeptide  (CYPA) except for the ones that are explicitly permitted; prohibited medications include but are not necessarily limited to alfuzosin, amiodarone, astemizole, bepridil, Chinese (herbal) medicines, cisapride, cyclosporine, cyclophosphamide, desipramine, erythromycin, etoposide, fentanyl, flecainide, flutamide, grapefruit and grapefruit juice, halofantrine, ifosfamide, imipramine, lovastatin, mexiletine, modafinil, oxycodone, pimozide, propafenone, quetiapine, quinidine, simvastatin, tacrolimus, tamoxifen, terfenadine, thioridazine, vinblastine and vincristine; exception: those patients who are in the translational sub-study will receive a low dose of fentanyl (a substrate of CYPA) during the surgical procedure (- mcg) for pain, along with ultra-short acting remifentanil (the latter has - min half-life)
Patients who are receiving drugs that significantly interact with the cytochrome P (CYP) enzyme(s) are ineligible; however, if they are switched to other medications with a -week washout window, they will be eligible; patients are also excluded if they have been exposed within  days of planned first study treatment day to medications that are predominantly cytochrome P, family , subfamily D, polypeptide  (CYPD), cytochrome P, family , subfamily C, polypeptide  (C) or cytochrome P, family , subfamily C, polypeptide  (C) substrates, strong inhibitors or inducers, and sensitive substrates of cytochrome P, family , subfamily A, polypeptide  (CYPA) with narrow therapeutic range
Less than  week since prior treatment (most recent dose) with a potent cytochrome P family , subtype A, polypeptide  (A) (CYPA) inhibitor
In vitro data indicate that GSK is a cytochrome P, family , subfamily A, polypeptide  (CYPA) substrate; drugs that potently inhibit CYPA could lead to increased GSK exposure in subjects, and should either be prohibited or used with caution; drugs which are strong inducers of cytochrome P, family , subfamily A (CYPA) and may result in lower exposures of GSK should also be prohibited; GSK also appears to be a moderate in vitro inhibitor of cytochrome P, family , subfamily C, polypeptide  (CYPC) (% inhibitory concentration [IC]  mcM) and CYPA (IC  mcM); drugs that are substrates of CYPA or CYPC with a narrow therapeutic index may be prohibited; drugs that are sensitive substrates of CYPA or CYPC should be used with caution
The eligibility of patients taking medications that are potent modulators of cytochrome P, family , subfamily A, polypeptide  (CYPA), cytochrome P, family , subfamily B, polypeptide  (CYPB), subfamily , polypeptide  (C) will be determined following a review of their case by the principal investigator; every effort should be made to switch patients taking such agents or substances to other medications
Evaluation of the patients medications within  days prior to registration with attempt to change any medication that affects cytochrome P, family , subfamily A, polypeptide  (CYPA)
Prohibited medications: PKC and its two major metabolites may have a potential of drug-drug interactions with P-gp substrates and cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors, and inducers; an increased anticoagulant effect has been noted in patients treated with warfarin and midostaurin
Patients taking substrates, inhibitors and inducers of cytochrome P family , subfamily A, polypeptide  (CYPA) should be encouraged to switch to alternative drugs whenever possible
Current or anticipated need for treatment with drugs that are known substrates of cytochrome P, family , subfamily D, polypeptide  (CYPD)
Patients currently taking the following medications:\r\n* Cytochrome P, family , subfamily C, polypeptide  (CYPC) inhibitors (e.g. Gemfibrozil)\r\n* CYPC inducers (e.g. rifampin)\r\n* Cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors (itraconazole)\r\n* CYPA inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine)
Finasteroid (propecia), efavirenz, red clover, ketoconazole and other drugs that are cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors
Treatment with strong cytochrome P, family , subfamily C, polypeptide  (CYPC), cytochrome P, family , subfamily A, polypeptide  (CYPA), and cytochrome P family  subfamily C member  (CYPC) inhibitors and/or inducers must be discontinued at least  week before administration of the first dose of study drug
Concurrent use of agents that strongly inhibit or induce cytochrome P family , subfamily A (CYPA) unless use is approved by the medical monitor
Concomitant use of medications that may alter pharmacokinetics of crizotinib or enzalutamide; would exclude the use of strong cytochrome P, family , subfamily A (CYPA) or cytochrome P, family , subfamily C, polypeptide  (CYPC) inhibitors, strong or moderate CYPA inducers, CYPC, cytochrome P, family , subfamily A, polypeptide  (CYPA), cytochrome P, family , subfamily C, polypeptide  (CYPC) and cytochrome P, family , subfamily C, polypeptide  (CYPC) substrates with narrow therapeutic indices
Concomitant use of narrow therapeutic index drugs that are metabolized by cytochrome P family , subfamily A, polypeptide  (CYPA) (i.e. alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus), cytochrome P family , subfamily C, polypeptide  (CYPC) (phenytoin, warfarin), and cytochrome P family , subfamily C, polypeptide  (CYPC) (S-mephenytoin); (Note: patients on stable doses of anti-coagulation with warfarin and fentanyl will be eligible, as long as they are monitored closely with additional international normalized ratio [INR] monitoring)
Mifepristone inhibits cytochrome P, family , subfamily A, polypeptide  (CYPA) and induces CYPA; addition of mifepristone to a pre-existing drug regimen may cause a mild and temporary increase in plasma drug concentration of drugs with significant CYPA metabolism; medications that are strong inducers of CYPA such as carbamazepine, oxcarbazepine, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentine, St. John's wort may decrease plasma mifepristone levels; strong CYPA inhibitor medications are expected to cause the largest increases in plasma mifepristone concentrations; mifepristone may increase the plasma drug concentration of concomitant medications with metabolism mediated by cytochrome P, family , subfamily C, polypeptide  (CYPC)/cytochrome P, family , subfamily C, polypeptide  (C)
Currently receiving treatment with agents that are metabolized solely through cytochrome P, family , subfamily A, polypeptide / (CYPA/) and have a narrow therapeutic index or are strong cytochrome P, family , subfamily C, polypeptide  (CYPC) inhibitors; or are receiving treatment with agents that carry a risk for QT prolongation and are CYPA substrates; caution should be used in patients taking other CYPC- or CYPA/-interacting agents
Inability to withhold agents that may interact with hepatic cytochrome P enzymes (cytochrome P family , subfamily A, polypeptide  [CYPA]), or glutathione S-transferases involved in bortezomib and/or busulfan metabolism during day - through day +; it is acceptable to use alternative non-interacting medications during this period, and then resume prior medications; importantly, no acetaminophen starting at HSCT admission, during conditioning chemotherapy and up to and including the stem cell infusion
Current systemic treatment with a potent cytochrome P family , subfamily A, polypeptide  (CYPA) inhibitor such as ketoconazole or ritonavir
Patients taking strong cytochrome P family , subfamily A, polypeptide  (CYPA) inhibitors including enzyme-inducing anti-epileptic drugs (phenytoin, carbazepine, or phenobarbitol), rifampin, grape fruit juice, or St. John's wort are not eligible
Drugs that are highly dependent on cytochrome P, family , subfamily A, polypeptide  (CYPA) for metabolism and have a narrow therapeutic index are allowed but must be used with caution
Medications with potent inducer or inhibitor of cytochrome P family , subfamily A, polypeptide  (P A) should be avoided within  half-lives of temsirolimus
Medications and/or diet are prohibited if they affect oral absorption of PF- or if primarily metabolized by cytochrome P, family , subfamily D, polypeptide  (CYPD); patients must have been off treatment with these drugs for  weeks prior to enrollment; patients who otherwise are eligible can be enrolled only if drug substitution is performed with acceptable clinical outcome prior to enrollment
Patients with a seizure disorder may be enrolled if well controlled on anticonvulsants at a dose that has been stable for at least  days; however, drugs that induce cytochrome P, family , subfamily A, polypeptide  (CYPA)/ (carbamazepine, oxcarbazepine, phenytoin, primidone, and phenobarbital) should be avoided
Drugs that potently inhibit cytochrome P family , subfamily A, polypeptide  (CYPA) should either be prohibited or used with caution; drugs which are strong inducers of cytochrome P family , subfamily A (CYPA) should also be prohibited; drugs that are substrates of CYPA or cytochrome P family , subfamily C, polypeptide  (CYPC) with a narrow therapeutic index may be prohibited; drugs that are sensitive substrates of CYPA or CYPC should be used with caution; it is important to regularly consult a frequently-updated list; medical reference texts such as the Physicians Desk Reference may also provide this information; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Drugs that are strong inhibitors or inducers of cytochrome P, family , subfamily A (CYPA) or cytochrome P, family , subfamily C, polypeptide  (CYPC), p-glycoprotein (Pgp) or ATP-binding cassette, sub-family G, member  (Bcrp) transporter; the list may be modified based on emerging data; consider therapeutic substitutions for these medications; patients must be off treatment for at least  week prior to enrollment
Ongoing treatment with sensitive cytochrome P, family , subfamily A, polypeptide  (CYPA) substrate or CYPA substrate with narrow therapeutic range at the start of study treatment
Concomitant use of drugs that strongly inhibit cytochrome P, family , subfamily A, polypeptide / (CYPA/)
Patients may not receive strong cytochrome P, family , subfamily C, polypeptide  (CYPC) inhibitors, CYPC inducers, or cytochrome P, family , subfamily A, polypeptide  (CYPA) inducers; in addition, patients should not receive drugs that are metabolized by CYPA or cytochrome P, family , subfamily C, polypeptide  (CYPC)
Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with LDK and for the duration of participation:\r\n* Medication with a known risk of prolonging the QT interval or inducing torsades de pointes\r\n* Strong inhibitors or strong inducers of cytochrome P, family , subfamily A poly peptide / (CYPA/)\r\n* Medications with a low therapeutic index that are primarily metabolized by CYPA/, and/or cytochrome P family , subfamily C, polypeptide  (CYPC)\r\n* Therapeutic doses of warfarin sodium (Coumadin) or any other coumarin-derived anti-coagulant; anti-coagulants not derived from warfarin are allowed (e.g., dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids\r\n* Enzyme-inducing anti-convulsive agents\r\n* Herbal supplements
Patients on any moderate or strong cytochrome P family , subfamily C, polypeptide  (CYPC) inducer (e.g., carbamazepine, rifampin) or inhibitor (e.g., amiodarone, fluconazole) are ineligible; CYPC poor metabolizers will not be excluded
Patients on narrow-therapeutic drugs that are substrates for cytochrome P family , subfamily A, polypeptide  (CYPA), CYPC, cytochrome P family , subfamily C, polypeptide  (CYPC), and cytochrome P family , subfamily A, polypeptide  (CYPA) are ineligible (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, phenytoin, pimozide, quinidine, sirolimus, tacrolimus, theophylline, tizanidine, warfarin)
Use of potent cytochrome P family , subfamily A, polypeptide  (A) (CYPA) inhibitor within one week of pacritinib initiation
Need for medications that strongly induce or inhibit cytochrome P, family , subfamily A, polypeptide  (CYPA) or cytochrome P, family , subfamily D, polypeptide  (CYPD) activity
Received potent cytochrome P, family , subfamily A (CYPA) inhibitors (e.g., ketoconazole) or inducers; or substrates of cytochrome P, family , subfamily D, polypeptide  (CYPD) with narrow therapeutic indexes within  days prior to the first dose of study drug
It should be noted that TAK- (orteronel) is a weak inhibitor of cytochrome P, family , subfamily A, polypeptide  (CYPA), cytochrome P, family , subfamily C, polypeptide  (C), and cytochrome P, family , subfamily C, polypeptide  (C); caution should be employed when used with medications that are strong/moderate inhibitors, significant inducers or sensitive substrates with narrow therapeutic indices
Use of rifampin (strong cytochrome P family , subfamily C, polypeptide  [CYPC] inducer) within  days of study day 
Patients may not be receiving agents thought to inhibit or induce the cytochrome p isoenzyme cytochrome P A (CYPA)
Patients cannot be taking any cytochrome P, cytochrome P, family , subfamily A, polypeptide  (CYPA) pathway inhibiting or inducing agents (except proton pump inhibitors which are allowed) including cimetidine, antidepressants, antibiotics and all others
Patients who are currently receiving drugs that are strong or moderate inhibitors and/or inducers of cytochrome P family  subfamily A polypeptide  (CYPA) or sensitive CYPA substrates and CYPA substrates with a narrow therapeutic range are not eligible; the use of aprepitant as an antiemetic is prohibited due to early drug interaction data demonstrating increased exposure to AZD; caution should be exercised with concomitant administration of AZD and agents that are sensitive substrates of cytochrome P family  subfamily C polypeptide  (CYPC), family  subfamily C polypeptide  (C) and family  subfamily C polypeptide  (C), or substrates of this enzyme with narrow therapeutic ranges, as well as agents that are inhibitors or substrates of P-glycoprotein (P-gp)
Concomitant use of known cytochrome P (family , subfamily A, polypeptide , ,  [A,,]) inducers such as carbamazepine, phenytoin, or oxcarbazepine
Use of select cytochrome P, family , subfamily D, polypeptide  (CYPD) inhibitor medications
Subjects being treated concurrently with any prohibited medications, including investigational medication, rifampin, St. Johns wort, and potent cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors (excluding ketoconazole) unless continuation of such medications are determined by the investigator to be in the best interest of the patient
Patients who are on strong inhibitors of cytochrome P family , subfamily C, polypeptide  (CYPC), strong or moderate inducers of cytochrome P family , subfamily A, polypeptide  (CYA) and CYPC should discontinue these medications  weeks prior to the start of treatment
Patients taking any potent inhibitor of cytochrome P family , subfamily A, polypeptide  (A) (e.g., ketoconozole, itraconozole, erythromycin, etc)
Taking medications known to affect drug metabolism via the cytochrome P, family , subfamily A, polypeptide  (CYPA), CYP, family , subfamily C, polypeptide  (CYPC), or CYP, family , subfamily D, polypeptide  (CYPD) pathways
Patients taking substrates, inhibitors, or inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA) should be encouraged to switch to alternative drugs whenever possible
